GSK
NEUTRALGSK Announces Director/PDMR Shareholding Transactions
The healthcare company has disclosed transactions involving the sale of ordinary shares by two senior executives.
GSK
1,778.50GBX
-0.53%
Market Cap
71.48B
Volume
12.86M
157% of avg
P/E Ratio
1058.63
EPS (TTM)
1.68
Beta
0.23
Day Range
1,769.00p - 1,788.00p
52 Week Range
1,242.50p1,778.50p1,799.00p
1,778.50p
Upcoming Events
GSK
VERY GOODGSK Delivers Strong Q3 Performance and Upgrades 2025 Guidance
The healthcare company reports strong Q3 results, upgrading its 2025 guidance for turnover, core operating profit and core EPS growth.
GSK
NEUTRALGSK's Antibody-Drug Conjugate Receives Orphan Drug Designation in EU
The healthcare company's new antibody-drug conjugate has received a regulatory designation in Europe, supporting its development in a rare form of lung cancer.
GSK
NEUTRALNo mandatory news type found in RNS
The RNS announcement does not contain any of the required news types for analysis.
GSK
NEUTRALGSK announces positive data for low carbon Ventolin MDI
The healthcare company has announced positive data for a low carbon version of its Ventolin metered dose inhaler, which could reduce greenhouse gas emissions by 92% per inhaler.
GSK
NEUTRALGSK provides update on latozinemab trial
The pharmaceutical company has reported results from a clinical trial of its latozinemab drug, which did not meet the primary endpoint.
GSK
NEUTRALGSK's Shingrix Vaccine Gets Positive CHMP Opinion for Prefilled Syringe
The healthcare company received a positive opinion from the European regulator for a new prefilled syringe version of its shingles vaccine Shingrix.
GSK
NEUTRALGSK's Oral Antibiotic Tebipenem HBr Meets Primary Endpoint in Phase 3 cUTI Trial
The healthcare company announced positive Phase 3 data for its oral antibiotic tebipenem HBr, which demonstrated non-inferiority to an intravenous treatment for complicated urinary tract infections.
GSK
NEUTRALGSK Directors Increase Shareholdings
The pharmaceutical company's directors have increased their shareholdings in the business through the re-investment of dividends.
GSK
NEUTRALGSK Directors Increase Shareholdings
The major pharmaceutical company has announced an increase in shareholdings by its directors and senior executives.